Assessment of relative efficiency of COVID-19 vaccines granted emergency use authorization in India and their respective modes of delivery-an economic evaluation
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233122Keywords:
COVID-19 vaccines, Economic evaluation, Cost of illness, Cost-effectiveness analysis, Cost-utility analysis, Relative efficiencyAbstract
Background: Effective public health interventions need to be assessed for efficiency in order to optimize results and justify investments especially under conditions of uncertainty and resource constraints. The COVID-19 pandemic has presented unprecedented situations where decisions had to be taken based on limited evidence available in order to save human lives. Vaccines have been identified to be the mainstay of the public health response to the pandemic. In India, nine vaccines have been granted emergency use authorization (EUA) and are being delivered through multiple modes. Efficiency of vaccine delivery needs to be established to maximize results and formulate policy in long run.
Methods: This study will be conducted in Delhi and Bhubaneshwar. Two systematic reviews, a cross-sectional community survey and a complete economic evaluation using a decision tree model will be carried out to meet the study objectives. Data will be captured through computer assisted personal interviewing (CAPI) using CS pro software. Outcomes will be measured in lives saved and quality adjusted life years (QALYs) gained by vaccination. This will be the first study providing a detailed cost of COVID-19 vaccination and treatment segregated by government or private provider
Conclusions: The study would establish the relative efficiency of each vaccine granted EUA over the other by their individual modes of delivery.
Metrics
References
WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. Available at: https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries. Accessed on 04 September, 2023
Banarjea A. Moderna's Covid vaccine becomes 4th jab to get emergency use approval in India: Govt. Mint. 2021.
Revised Guidelines for implementation of National COVID Vaccination Program. Available at: https://nhsrcindia.org/sites/default/files/2021-07/Revisedpdf. Accessed on 04 September, 2023.
Ministry of Health and Family Welfare GoI. Frequently Asked Questions India. 2021.
Johnson and Johnson’s single-dose COVID-19 vaccine approved for emergency use in India. The Hindu. 2021.
Lab GCD. India: Coronavirus Pandemic Country Profile United Kingdom: Global Change Data Lab. 2023. Available at: https://ourworldindata.org/ coronavirus/country/india. Accessed on 04 September, 2023.
Nada Hamadeh CVR, Eric, Metreau, Shwetha Grace Eapen. World Bank Blogs [Internet]: World Bank Group. 2022. Available from: https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2022-2023. accessed on 26.09.2023.
Unnikrishnan J, Mangalathu S, Kutty RV. Estimating under-reporting of COVID-19 cases in Indian states: an approach using a delay-adjusted case fatality ratio. BMJ Open. 2021;11(1):e042584.
Purkayastha S, Kundu R, Bhaduri R, Barker D, Kleinsasser M, Ray D et al. Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. BMC Res Notes. 2021;14(1):262.
Zimmermann LV, Salvatore M, Babu GR, Mukherjee B. Estimating COVID-19-Related Mortality in India: An Epidemiological Challenge With Insufficient Data. Am J Publ Heal. 2021;111(S2):S59-62.
Sneha Mordani PA. Kerala and Maharashtra did least under reporting of Covid cases: ICMR study. India Today. 2021.
Orangi S, Ojal J, Brand SP, Orlendo C, Kairu A, Aziza R et al. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya. BMJ Glob Health. 2022;7(8).
Pearson CAB, Bozzani F, Procter SR, Davies NG, Huda M, Jensen HT et al. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness. PLoS Med. 2021;18(10):e1003815.
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J et al. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open. 2022;12(9):e061752.
Shaker M, Abrams EM, Greenhawt M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. J Allergy Clin Immunol Pract. 2021;9(7):2658-68.
Siedner MJ, Alba C, Fitzmaurice KP, Gilbert RF, Scott JA, Shebl FM et al. Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries. J Infect Dis. 2022;226(11):1887-96.
Vaezi A, Meysamie A. COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines (Basel). 2021;10(1).
